Texas Risperdal Lawyer


Risperdal LawsuitRisperdal (risperidone) is a medication used to treat psychotic disorders. It has been linked to many severe side effects, especially when it is prescribed “off-label” to children. These side effects include “medically serious” weight gain, enlargement of male breasts (gynecomastia), diabetes, and more.

Do I Have a Risperdal Lawsuit? Collen A. Clark is a true advocate for his clients and is passionate about helping Texans that have been injured or wronged. If you or a loved one has been injured after taking Risperdal, you should contact our lawyers immediately. You may be entitled to compensation by filing a Risperdal lawsuit or joining a class action.

UPDATE: Risperdal Trial Ends in Settlement for Boy With Gynecomastia

May 27, 2015 — Just hours into opening arguments, Johnson & Johnson has settled a lawsuit filed on behalf of a boy from California who developed gynecomastia (female breasts) after taking Risperdal. Click here to read more.

March 18, 2015 — A jury in Philadelphia has ordered Johnson & Johnson to pay $2.5 million to a 22 year-old autistic man who developed size 46DD breasts after taking Risperdal “off-label” as a child. Click here to read more.

February 12, 2015 — A lawsuit has been filed by a man who was prescribed Risperdal as a child and developed gynecomastia (enlarged breasts). Click here to read more.

January 30, 2015 — Dr. David Kessler, a pediatrician and former commissioner of the FDA, has testified in a trial accusing Johnson & Johnson of failing to warn that Risperdal could cause gynecomastia (breast enlargement) in young boys. Click here to read more.

January 27, 2015 — The doctor who prescribed Risperdal to a child who developed gynecomastia has testified that he would have re-evaluated his decision if Janssen Pharmaceuticals had adequately warned about the side effect. Click here to read more.

January 26, 2015 — Attorneys representing an autistic boy who developed enlarged breast tissue (gynecomastia) after taking Risperdal have presented opening arguments to a jury in Philadelphia, in one of the first cases to go to trial. Click here to read more.

December 18, 2014 — Over 1,000 lawsuits involving Risperdal have been filed, with the latest case involving a boy from Louisiana who was diagnosed with gynecomastia (male breasts) after taking the medication “off-label” when he was just a child. Click here to read more.

September 9, 2014 — A recent study has found that 0.72% of children on anti-psychotic drugs like Risperdal developed diabetes, compared to just 0.27% of children who did not take the drugs. Click here to read more.

August 22, 2014 — Middle-aged men who use Risperdal face a 69% increased risk of gynecomastia (male breast growth) compared to men who do not take anti-psychotic drugs, according to a study published in the Journal of Clinical Psychopharmacology. Click here to read more.

August 21, 2014 — The Annals of Internal Medicine has published a study linking the use of popular atypical antipsychotic drugs in older adults with a 73% increased risk of hospitalization for acute kidney injury and other severe side effects. Click here to read more.

June 24, 2014 — A lawsuit (PDF) has been filed by a 27 year-old man who took Risperdal and developed severely enlarged breasts that had to be treated with a double mastectomy. Click here to read more.

June 19, 2014 — Law360 reports that attorneys for victims of Risperdal are asking a Philadelphia judge to reconsider a decision banning them from seeking punitive damages against Johnson & Johnson and its Janssen Pharmaceuticals unit. Click here to read more.

May 29, 2014 — Attorneys for Johnson & Johnson and Janssen have asked a Philadelphia judge to throw out time-barred lawsuits involving Risperdal. If the judge agrees, hundreds of cases could be thrown out of the litigation because the “statute of limitations” has expired on their claim. Click here to read more.

May 14, 2014 — The Pennsylvania judge overseeing more than 500 lawsuits involving Risperdal has banned plaintiffs from seeking punitive damages, ruling that a New Jersey law will apply to cases in the Philadelphia Court of Common Pleas. Click here to read more.

March 20, 2014 — The Arkansas Supreme Court has tossed a $1.2 billion judgement against Johnson & Johnson for illegally marketing Risperdal. J&J has also successfully overturned a $258 million award in Louisiana. A $327 million penalty in South Carolina is being appealed. Click here to read more.

March 18, 2014 — Researchers have presented data from a study linking the use of Risperdal to a 69% increased risk of gynecomastia (male breast growth) in older men. Click here to read more.

March 11, 2014 — J&J and Janssen will pay $5.9 million to settle a Risperdal lawsuit in Montana. The case was filed in 2008 by the state attorney general, Tim Fox, who accused the drug-makers of using misleading and illegal marketing tactics to market Risperdal. Click here to read more.

November 13, 2013 — Evidence that Risperdal clinical trial data was withheld for years. Click here to read more.

November 4, 2013 — Johnson & Johnson (J&J) will pay $2.2 billion to settle criminal and civil fines with the Department of Justice (DOJ) that they improperly marketed Risperdal to elderly dementia patients and children who developed severe side effects, including gynecomastia and type-2 diabetes. Click here to read more.

Risperdal Overview

Risperdal (risperidone) is an antipsychotic drug that treats several severe mood disorders. It was first approved by the U.S Food and Drug Administration (FDA) in 1993 for the treatment of schizophrenia in adults; since then, it has been approved for several other conditions. Risperdal was manufactured by the drug company Janssen, which is now a unit of Johnson & Johnson.

Risperdal and Gynecomastia

Risperdal has been associated with an increase in levels of a hormone called prolactin, which plays many roles in the body — including growth of breast tissue. In females, this can cause a condition called glactorrhea, or production of milk. In males, excessive prolactin can cause a condition called gynecomastia.

Gynecomastia is the growth or enlargement of male breast tissue. The tissue is non-cancerous and poses no physical health risks; however, the psychological and social injuries can be devastating — especially when gynecomastia affects adolescent males. Many doctors recommend surgery to reduce breast tissue. In mild or moderate cases, liposuction may be an effective option. In severe cases, however, a surgical procedure called a mastectomy may be necessary to remove breast tissue and excess skin.

At least as early as 1999, researchers have linked the use of Risperdal to gynecomastia. Several studies have verified an association between Risperdal and gynecomastia, especially in young males. This study, published in Journal of Clinical Psychopharmacology in 2006, warned:

Risperidone administered to adolescents at doses commonly used for the treatment of psychotic symptoms can strongly increase prolactin levels, with clinical consequences such as gynecomastia and/or galactorrhea. Given that the long-term effects of antipsychotic drug-induced hyperprolactinemia are not well documented, especially regarding osteopenia, infertility, growth, and pubertal delay, risperidone should be administered with caution to children and adolescents.”

Risperdal Lawsuit Settlements

In September 2012, Johnson & Johnson settled a lawsuit filed by a young man who took Risperdal as a child and suffered severe gynecomastia, which required surgical treatment. Aron Banks used Risperdal when he was between the ages of 9 and 14, from 1999 until 2004. On the first day of the trial, Mr. Banks agreed to a settlement with Johnson & Johnson. As part of the agreement, the amount of the settlement remains confidential.

As of September 2012, there are an additional 420 lawsuits pending in courthouses throughout the United States. Of these, 130 involve gynecomastia claims.

J&J Pays Billions for “Off-Label” Risperdal Marketing

Johnson & Johnson has already settled several federal and state lawsuits brought by government attorneys. These lawsuits allege that the company engaged in illegal off-label marketing, created a pay-off scheme to incentivize nursing homes to prescribe Risperdal (despite the fact that Risperdal increases the risk of death among elderly people with dementia), and defrauded the state Medicare system.

Johnson & Johnson has already settled with the U.S. Justice Department for $2.2 billion. In January 2012, the company also agreed to settle with Texas State Attorney General for $158 million to prevent the lawsuit from going to trial. Several other states have also filed lawsuits.

Studies Link Risperdal and Diabetes

Risperdal is associated with an increased risk of type-2 diabetes and hyperglycemia (high blood-sugar) in children and adults. Risperdal can lead to the development of “medically serious” weight gain, which predisposes patients to diabetes. Click here to read more.

  • Pharmacotherapy (2003), “Risperidone-associated diabetes mellitus: a pharmacovigilance study” — 131 cases of high blood-sugar (hyperglycemia) linked to the use of Risperdal.
  • American Journal of Epidemiology (2006), “Diabetes Risk Associated with Use of Olanzapine, Quetiapine, and Risperidone in Veterans Health Administration Patients with Schizophrenia” — Study links Risperdal and weight-gain that “may contribute to the increased risk of diabetes.”

Risperdal Side Effects

Do I have a Risperdal Lawsuit?

Collen A. Clark is a true advocate for his clients and is passionate about helping Texans that have been injured or wronged.

Collen’s amazing success in the courtroom and well known dedication to his clients has earned him the recognition of his peers as one of The Top Trial Lawyers in Texas.”

The Clark Firm has assembled a team of trial lawyers with more than 100 years experience, participation in over 600 jury trials and $60 million in verdicts and/or settlements. Please use the form below to contact us for a free Texas Risperdal lawsuit review.

Free Case Review

To contact us for a free review of your potential case, please fill out the form below or call us toll free 24 hrs/day by dialing: (866) 879-3040.

Fields marked with * are required